Research programme: tumour suppressing gene therapies - Introgen
Alternative Names: INGN 402; INGN 403; Nanoparticle formulation mda-7; Nanoparticle formulation p53Latest Information Update: 18 Feb 2010
At a glance
- Originator Introgen Therapeutics
- Class Gene therapies
- Mechanism of Action Gene transference; Interleukin 24 stimulants; P53 gene stimulants; Tumour suppressor gene transcription stimulants; Tumour suppressor protein p53 stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Solid tumours